Literature DB >> 17387152

Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.

Tsutomu Yamazaki, Tsuguo Sasaki, Masahiro Takahata.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17387152      PMCID： PMC1891417          DOI： 10.1128/AAC.01561-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  13 in total

1.  Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro.

Authors:  N Okazaki; M Narita; S Yamada; K Izumikawa; M Umetsu; T Kenri; Y Sasaki; Y Arakawa; T Sasaki
Journal:  Microbiol Immunol       Date:  2001       Impact factor: 1.955

2.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae.

Authors:  Satowa Suzuki; Tsutomu Yamazaki; Mitsuo Narita; Norio Okazaki; Isao Suzuki; Tomoaki Andoh; Mayumi Matsuoka; Tsuyoshi Kenri; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Erythromycin resistance by ribosome modification.

Authors:  B Weisblum
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

5.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 6.  Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections.

Authors:  D Taylor-Robinson; C Bébéar
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

7.  Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA.

Authors:  S Douthwaite; L H Hansen; P Mauvais
Journal:  Mol Microbiol       Date:  2000-04       Impact factor: 3.501

Review 8.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

9.  In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

Authors:  S Pereyre; H Renaudin; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more
  2 in total

1.  Mycoplasma pneumoniae-derived lipopeptides induce acute inflammatory responses in the lungs of mice.

Authors:  Takashi Shimizu; Yutaka Kida; Koichi Kuwano
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

Review 2.  Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment.

Authors:  Sabine Pereyre; Julien Goret; Cécile Bébéar
Journal:  Front Microbiol       Date:  2016-06-22       Impact factor: 5.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.